| Analysts were expecting Vertex Pharmaceuticals Incorporated (VRTX) [Chart - News - Analysis] to report earnings of $-0.81 for last quarter, but VRTX missed expectations with actual earnings of $-0.84---3 cents below the consensus estimate. If you compare last quarter's earnings to the $-0.93 the company made per share during the same quarter a year ago, you can see that VRTX’s earnings are up this year. Check this out (it's free!): Stocks You Should Be Watching Right Now; How to Make Good Picks
| | | | | |
-
Essential Reading for Traders
-
| | |
| | | | | | | | Also, if you compare VRTX's 0.00% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 16.79% for the Drug Manufacturers - Other industry as a whole during that same time frame, you can see that analysts expect VRTX to underperform the industry in the future---which is a bad sign for the stock. Drilling down a little deeper into the Drug Manufacturers - Other industry, you can see how analysts believe VRTX will stack up against some of the other stocks in the industry, like Dr. Reddy's Laboratories Ltd. (RDY) [Chart - News - Analysis] and Allergan Inc. (AGN) [Chart - News - Analysis], in the future. Analysts believe RDY's earnings are going to grow at a rate of 21.00% while AGN's earnings are going to grow at a rate of 13.31%. Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements. - Earnings Season is Here - Find Out How to Trade It - Using Options to Trade Earnings - Understanding Stock Analyst Research and Recommendations More...
Keep up with us:
| 
